Dabrafenib |
Small-molecule, ATP-competitive inhibitor of the rapidly accelerated fibrosarcoma (RAF) kinases, especially mutant BRAF. |
Dacomitinib |
Small-molecule, irreversible inhibitor of the pan-human epidermal growth factor receptor (HER) family. |
Doxorubicin and epirubicin |
Chemotherapeutic agents belonging to the class of anthracyclines, acting by multiple mechanisms including (1) intercalating between base pairs in the DNA helix, (2) inhibiting topoisomerase 2, and (3) forming oxygen free radicals. |
Everolimus |
Allosteric inhibitor of the mammalian target of rapamycin (mTOR), inhibiting the mTOR functional complex mTORC1. |
Fulvestrant |
Selective estrogen receptor downregulator or degrader, competitively binding to estrogen receptors and promoting their degradation. |
Infigratinib |
Pan-inhibitor of human fibroblast growth factor receptors (FGFRs). |
JQ1 |
Small molecule, competitive inhibitor of bromodomain-containing 4 (BRD4), an epigenetic reader acting as transcriptional regulator. |
Lapatinib |
Small molecule, ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). |
Neratinib |
Small molecule, irreversible inhibitor of EGFR and HER2. |
Palbociclib |
Cyclin-dependent kinase 4 and 6 inhibitor, preventing retinoblastoma (Rb) protein phosphorylation and leading to cell cycle arrest. |
Ponatinib |
Small molecule, multitargeted tyrosine kinase inhibitor, inhibiting, among others, BCR-ABL, vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), TEK Receptor Tyrosine Kinase (TIE2), FMS-like tyrosine kinase 3 (FLT3), KIT, and REarranged during Transfection (RET). |
Selumetinib |
Small molecule, allosteric inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. |
SHP099 |
Small molecule, allosteric inhibitor of Srchomology-2-domain-containing PTP 2 (SHP2). |
Sorafenib |
Small molecule, multitargeted tyrosine kinase inhibitor, inhibiting, among others, RAF, VEGFR 1/2/3, platelet-derived growth factor receptor (PDGFR) beta, KIT, FLT3, FGFR1, and RET. |
Tamoxifen |
Selective estrogen receptor modulator (SERM), competitively inhibiting the binding of estradiol to estrogen receptors. |
Trametinib |
Small molecule, allosteric inhibitor of MEK1 and MEK2. |
Trastuzumab |
Recombinant humanized monoclonal antibody targeting the extracellular domain of HER2. |
Tucatinib |
ATP-competitive, small molecule inhibitor of HER2. |
Ulixertinib |
Small molecule, ATP-competitive inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2. |
Vemurafenib |
ATP-competitive, small-molecule inhibitor of mutant BRAF, including BRAF(V600E). |